Skip to main content

Table 1 Univariate Cox and logistic regression within tumor subtypes and multivariate Cox and logistic regression in patients with HR+/HER2− breast cancer for comparing tumors with high vs. low HLA class I immunohistochemistry

From: Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Univariate Cox regression—disease-free survival (GeparTrio)

 Subtype

MHCI

HR

95% CI

P

 HR+/HER2−

High vs. low

1.590

1.062–2.380

0.024

 HR−/HER2−

High vs. low

0.649

0.315–1.336

0.241

 HR+/HER2+

High vs. low

2.486

0.956–6.467

0.062

 HR−/HER2+

High vs. low

1.015

0.304–3.384

0.981

Multivariate Cox regression—disease-free survival (GeparTrio; HR+/HER2−)

  

HR

95% CI

P

 Response

pCR vs. RD

0.457

0.225–0.925

0.029

 cT stage

cT3–4 vs. cT1–2

2.270

1.522–3.385

< 0.001

 cN stage

cN+ vs. cN−

2.026

1.335–3.075

0.001

 Therapy

Resp. guided vs. standard

0.945

0.638–1.400

0.777

 Grade

G3 vs. G1–2

1.733

1.024–2.932

0.041

 Age

Age ≥ 50 vs. < 50

1.252

0.838–1.870

0.272

 HLA class I HC

High vs. low

1.701

1.105–2.618

0.016

Univariate logistic regression—pCR (GeparTrio)

 Subtype

MHCI

HR

95% CI

P

 HR+/HER2−

High vs. low

2.226

1.154–4.585

0.022

 HR−/HER2−

High vs. low

0.852

0.332–2.316

0.744

 HR+/HER2+

High vs. low

2.022

0.728–6.590

0.202

 HR−/HER2+

High vs. low

0.857

0.220–3.385

0.823

Multivariate logistic regression—pCR (GeparTrio; HR+/HER2−)

  

HR

95% CI

P

 cT stage

cT3–4 vs. cT1–2

0.946

0.447–1.903

0.880

 cN stage

cN+ vs. cN-

1.107

0.579–2.135

0.760

 Therapy

Resp. guided vs. standard

0.842

0.444–1.578

0.593

 Grade

G3 vs. G1–2

2.804

1.348–5.644

0.005

 Age

Age ≥ 50 vs. < 50

0.564

0.297–1.055

0.075

 HLA class I HC

High vs. low

2.132

1.057–4.603

0.042